title: Chemotherapy of MMR-deficient colorectal cancer.
abstract: Colorectal cancer (CRC) continues to rank as the third most common cancer in Western society and the second leading cause of cancer death in North America. There are at least three distinct, and relatively discreet, molecular pathways associated with this disease: chromosomal instability (CIN), microsatellite instability (MSI) and the cytosine polyguanine island methylator phenotype. Defects in the DNA mismatch repair system (MMR) account for the MSI phenotype and genotype of about 15 % of CRC. Although high frequency MSI tumors have better stage independent prognosis compared to those with CIN, MMR deficient CRC appears to be resistant to fluorouracil based treatment, but sensitive to other therapeutic regimens. This review summarises current literature on differential chemosensitivity of MMR-deficient CRC.
authors.affiliation: Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
authors.forename: N
authors.initials: N
authors.lastname: Devaud
authors.forename: S
authors.initials: S
authors.lastname: Gallinger
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D053843:DNA Mismatch Repair; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D053842:Microsatellite Instability
chemical_list: D000970:Antineoplastic Agents
references.citation: Gastroenterology. 2006 Sep;131(3):729-37
references.pmid: 16952542
references.citation: Cancer Res. 2001 Jul 1;61(13):5193-201
references.pmid: 11431359
references.citation: Science. 1991 Aug 9;253(5020):665-9
references.pmid: 1651563
references.citation: N Engl J Med. 2000 Jan 13;342(2):69-77
references.pmid: 10631274
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23
references.pmid: 11535541
references.citation: Pharmacol Ther. 1990;48(3):381-95
references.pmid: 1707544
references.citation: Nat Rev Clin Oncol. 2010 Mar;7(3):174-7
references.pmid: 20190798
references.citation: Anticancer Res. 2004 Sep-Oct;24(5B):3161-7
references.pmid: 15510606
references.citation: Cancer Res. 1998 Nov 15;58(22):5248-57
references.pmid: 9823339
references.citation: Cancer Res. 2003 Sep 15;63(18):5738-44
references.pmid: 14522894
references.citation: Ann Oncol. 2010 Apr;21(4):772-780
references.pmid: 19833818
references.citation: CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1
references.pmid: 10200775
references.citation: Cancer Res. 2001 Sep 1;61(17):6555-62
references.pmid: 11522654
references.citation: Anticancer Res. 2000 Jan-Feb;20(1A):85-90
references.pmid: 10769638
references.citation: J Clin Oncol. 2005 Jan 20;23(3):609-18
references.pmid: 15659508
references.citation: J Clin Oncol. 1993 Oct;11(10):1879-87
references.pmid: 8410113
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3219-26
references.pmid: 20498393
references.citation: Cancer Res. 1995 Dec 1;55(23):5548-50
references.pmid: 7585632
references.citation: Anticancer Res. 2007 Jul-Aug;27(4C):2715-9
references.pmid: 17695437
references.citation: Cancer Res. 1997 May 15;57(10):1841-5
references.pmid: 9157971
references.citation: Science. 1997 Feb 14;275(5302):967-9
references.pmid: 9020077
references.citation: Science. 1993 May 7;260(5109):816-9
references.pmid: 8484122
references.citation: Int J Cancer. 2003 Aug 10;106(1):66-73
references.pmid: 12794758
references.citation: CA Cancer J Clin. 1985 Nov-Dec;35(6):345-7
references.pmid: 3931867
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3380-7
references.pmid: 20516444
references.citation: J Clin Oncol. 2007 Mar 1;25(7):767-72
references.pmid: 17228023
references.citation: Hum Mol Genet. 2004 Dec 1;13(23):2937-45
references.pmid: 15459181
references.citation: J Clin Oncol. 1999 Nov;17(11):3553-9
references.pmid: 10550154
references.citation: J Clin Oncol. 2006 May 20;24(15):2359-67
references.pmid: 16710035
references.citation: Gut. 1998 May;42(5):673-9
references.pmid: 9659163
references.citation: Cancer Res. 2009 Apr 1;69(7):2853-60
references.pmid: 19318581
references.citation: Cell. 1993 Dec 17;75(6):1215-25
references.pmid: 8261515
references.citation: J Clin Oncol. 2004 Aug 15;22(16):3408-19
references.pmid: 15199089
references.citation: Gastroenterology. 1993 May;104(5):1535-49
references.pmid: 8482467
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2198-204
references.pmid: 17470851
references.citation: J Clin Oncol. 2002 Feb 15;20(4):1043-8
references.pmid: 11844828
references.citation: N Engl J Med. 2004 Jun 3;350(23):2343-51
references.pmid: 15175436
references.citation: Cancer Res. 1997 Aug 1;57(15):3253-7
references.pmid: 9242457
references.citation: Lancet. 2000 May 20;355(9217):1745-50
references.pmid: 10832824
references.citation: N Engl J Med. 1990 Feb 8;322(6):352-8
references.pmid: 2300087
references.citation: N Engl J Med. 2003 Jul 17;349(3):247-57
references.pmid: 12867608
references.citation: Med Oncol. 2010 Dec;27(4):1277-85
references.pmid: 19949897
references.citation: Int J Cancer. 2002 Sep 1;101(1):23-31
references.pmid: 12209584
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3109-16
references.pmid: 19451431
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15
references.pmid: 18990764
references.citation: Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67
references.pmid: 20033812
references.citation: J Clin Oncol. 2011 Apr 1;29(10):1261-70
references.pmid: 21383284
references.citation: J Clin Oncol. 1998 Jan;16(1):295-300
references.pmid: 9440756
references.citation: EMBO Mol Med. 2009 Sep;1(6-7):323-37
references.pmid: 20049736
references.citation: Cell. 1993 Dec 3;75(5):1027-38
references.pmid: 8252616
references.citation: Gastroenterology. 2000 Oct;119(4):921-8
references.pmid: 11040179
references.citation: Science. 1993 May 7;260(5109):810-2
references.pmid: 8484120